logo-loader
viewCallitas Health Inc

Third study backs M Pharmaceutical weight loss side-effect claims

Orlistat is the best-selling weight loss drug of all time but use is limited by so-called “socially unacceptable bowel-related side effects”. That's all about to change thanks to M Pharmaceutical.

Fat man sitting on a toilet
90% of orlistat users have experienced “underwear issues”.

M Pharmaceutical Inc (CNQ:MQ) has proved the efficacy of it weight loss medication C-103 for a third time.

The third study, conducted in India, found that C-103 was over 97% effective in eliminating the adverse gastro-intestinal effects associated with weight loss medication orlistat.

Orlistat is the best-selling weight loss drug of all time with peak sales of over US$900mln in 2007, but use is limited by so-called “socially unacceptable bowel-related side effects” - namely incontinence and “flatus with discharge”.

FDA research found that over 90% of orlistat users have experienced “underwear issues”.

C-103 is a novel formulation of the drug designed to reduce these unpleasant side effects.

Thursday’s findings are consistent with the first and second of the three pilot study findings announced in August, which both found C-103 was over 98% effective in eliminating the side effects.

"M Pharma's review and assessment of these three studies fully supports our business objective to advance toward the commercialization of C-103, with the goal of helping millions of people to reach and maintain a healthy weight,” added chief executive Brian Keane.

 

Quick facts: Callitas Health Inc

Price: - CAD

CSE:LILY
Market: CSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

iCoreConnect cloud-based software is a real game changer in healthcare

iCoreConnect (OTCQB: ICCT) President and CEO Robert McDermott joined Steve Darling from Proactive to discuss the company that provides HIPAA-compliant software for the medical and dental industries. McDermott discusses a few of their services, their recent revenue growth and why listing on...

13 hours, 11 minutes ago

2 min read